| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019994 |
| Receipt No. | R000022715 |
| Official scientific title of the study | Efficacy test of the moisturizer JI1 |
| Date of disclosure of the study information | 2015/11/30 |
| Last modified on | 2016/05/26 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Efficacy test of the moisturizer JI1 | |
| Title of the study (Brief title) | Efficacy test of the moisturizer JI1 | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To confirm the moisturizing activity and the mechanism of the active ingredient for healthy skin |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Change of water content, transepidermal water loss, visual score and texture after the topical application for 4, 8, 12 weeks |
| Key secondary outcomes | Change of cell morphology and the composition of stratum corneum after the topical application for 4, 8, 12 weeks |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Self control |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Apply the formulation including an active ingredient to the half of facial skin twice daily for 12 weeks
Apply the placebo formulation to the another half of facial skin twice daily for 12 weeks |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Healthy females | |||
| Key exclusion criteria | -Subjects with cutaneous symptoms of atopic dermatitis
-Pregnancies and lactations -Subjects undergoing hormon therapy -Subjects participation in another clinical study accompanied by topical application of formulations and tape stripping or delipidation treatment to obtain experimantal dry skin to the sites to be studied within the past 1 month -Subjects deemed inappropriate to participate in this study by the parinciple investigator |
|||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Yukiyoshi Katsumata |
| Organization | EXAM CO., LTD |
| Division name | Cosmetic Laboratory Department |
| Address | H.O/2. Nishi 5-chome, Kita-1-jo, Chuo-ku, Sapporo, Hokkaido, 060-001, JAPAN |
| TEL | 011-205-0781 |
| dermalabo@ekusamu.co.jp | |
| Public contact | |
| Name of contact person | Yukiyoshi Katsumata |
| Organization | EXAM CO., LTD |
| Division name | Cosmetic Laboratory Department |
| Address | H.O/2. Nishi 5-chome, Kita-1-jo, Chuo-ku, Sapporo, Hokkaido, 060-001, JAPAN |
| TEL | 011-205-0781 |
| Homepage URL | |
| dermalabo@ekusamu.co.jp | |
| Sponsor | |
| Institute | EXAM CO.,LTD |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 株式会社エクサムデルマラボ事業部(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022715 |